Stock Events

Stock Events

Alterity Therapeutics 

€0
0
-€0-20% Friday 11:02

Statistics

Day High
0
Day Low
0
52W High
0.01
52W Low
0
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

25FebExpected
Q4 2025
-0
-0
-0
-0
Expected EPS
-0.00032475257675
Actual EPS
-0.000508308381

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PBN.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap26.03B
Biogen focuses on neurodegenerative diseases, directly competing with Alterity's focus on Parkinson's and Alzheimer's.
Palatin Technologies
PTN
Mkt Cap31.4M
Palatin Technologies works on novel therapeutics for diseases with a significant unmet medical need, including neurological disorders.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.78B
Acadia Pharmaceuticals specializes in central nervous system disorders, making it a direct competitor in the neurodegenerative disease space.
AnaptysBio
ANAB
Mkt Cap1.66B
AnaptysBio is involved in developing therapeutic antibodies, potentially competing in the neurodegenerative disease treatment market.
Anavex Life Sciences
AVXL
Mkt Cap277.09M
Anavex Life Sciences Corp. focuses on developing drugs for Alzheimer's disease and other central nervous system diseases.
Axsome Therapeutics
AXSM
Mkt Cap8.62B
Axsome Therapeutics develops therapies for central nervous system disorders, including Alzheimer's, directly competing with Alterity.
Ionis Pharmaceuticals
IONS
Mkt Cap12.35B
Ionis Pharmaceuticals develops RNA-targeted therapeutics, including for neurological disorders, competing in the same space as Alterity.
Prothena
PRTA
Mkt Cap530.79M
Prothena Corporation is focused on the discovery and development of novel antibodies for neurodegenerative diseases.
Voyager Therapeutics
VYGR
Mkt Cap236.01M
Voyager Therapeutics focuses on severe neurological diseases through gene therapy, competing in the broader neurodegenerative treatment market.

About

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Show more...
CEO
Dr. David A. Stamler M.D.
Employees
9
Country
Australia
ISIN
AU0000043945

Listings

MU
DE
PBN0.MU
AU
AU
ATH.AU
STU
DE
PBN.STU
STU
DE
PBN0.STU

0 Comments

Share your thoughts

FAQ

What is Alterity Therapeutics stock price today?▼
The current price of PBN.STU is €0 EUR — it has decreased by -20% in the past 24 hours. Watch Alterity Therapeutics stock price performance more closely on the chart.
What is Alterity Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alterity Therapeutics stocks are traded under the ticker PBN.STU.
Is Alterity Therapeutics stock price growing?▼
PBN.STU stock has fallen by -20% compared to the previous week, the month change is a -20% fall, over the last year Alterity Therapeutics has showed a -20% decrease.
When is the next Alterity Therapeutics earnings date?▼
Alterity Therapeutics is going to release the next earnings report on August 28, 2026.
What were Alterity Therapeutics earnings last quarter?▼
PBN.STU earnings for the last quarter are -0 EUR per share, whereas the estimation was -0 EUR resulting in a -56.52% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Alterity Therapeutics have?▼
As of April 11, 2026, the company has 9 employees.
In which sector is Alterity Therapeutics located?▼
Alterity Therapeutics operates in the Health & Wellness sector.
When did Alterity Therapeutics complete a stock split?▼
Alterity Therapeutics has not had any recent stock splits.
Where is Alterity Therapeutics headquartered?▼
Alterity Therapeutics is headquartered in Melbourne, Australia.